We are international

Sydney 2005:
Bisphosphonates and the Bone Microenvironment
By Peter Croucher, MD

Dr. Croucher outlined bisphosphonates and the bone marrow microenvironment. Managing bone disease is necessary for MM patients. To date, only bisphosphonates are used to treat bone disease in MM patients. Research in animal models of bone disease shows differences between the various bisphosphonate agents. Pamidronate and zoledronate improve survival in a myeloma model; ibandronate has no effect on survival in the same model. Croucher and colleagues suggest that treatment with bisphosphonates may have an anti-myeloma effect that may be mediated in part by inhibiting bone resorption.

Back to session summary

 related articles